Hepatitis B

Subscribe to Selected New Research on Hepatitis B

11093 relevant articles (656 outcomes, 985 trials/studies) found for this Disease

Description: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.

Relationship Network

Disease Context: Research Results

Virus Diseases: 1376

Human Viral Hepatitis: 26

Hepatitis B: 11093

Chronic Hepatitis B: 4353

DNA Virus Infections: 23

Hepadnaviridae Infections

Hepatitis B: 11093

Chronic Hepatitis B: 4353

Digestive System Diseases: 31

Liver Diseases: 20042

Hepatitis: 17547

Human Viral Hepatitis: 26

Hepatitis B: 11093

Chronic Hepatitis B: 4353

Related Diseases

1.	Infection
2.	Chronic Hepatitis B
3.	Hepatitis
4.	Liver Diseases (Liver Disease)
5.	Fibrosis (Cirrhosis)

Experts

1.	Kao, Jia-Horng: 19 articles (08/2008 - 01/2002)
2.	Chen, Ding-Shinn: 17 articles (08/2008 - 01/2002)
3.	Chen, Pei-Jer: 16 articles (08/2008 - 01/2002)
4.	Lai, Ming-Yang: 12 articles (08/2008 - 01/2002)
5.	Liu, Chun-Jen: 12 articles (08/2008 - 01/2002)
6.	Neuhaus, P: 9 articles (09/2002 - 01/2000)
7.	Lok, Anna S F: 8 articles (04/2008 - 08/2003)
8.	Lai, Ching-Lung: 8 articles (12/2007 - 11/2002)
9.	Neuhaus, Peter: 8 articles (03/2007 - 06/2002)
10.	Samuel, Didier: 8 articles (03/2007 - 12/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hepatitis B:

1.	AntigensIBA 12/01/1978 - "Eight of ten in the hepatitis B antigen-postive group cleared their antigen and had complete clinical recovery. " 07/01/2001 - "In adults at risk for a reduced response to hepatitis B vaccination [i.e., older adults (>/=40), the obese, males, and smokers], the triple antigen vaccine produced a significantly greater percentage of protected subjects (P < 0.001) and higher geometric mean titre (P < 0.001). " 07/01/2002 - "Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored." 12/01/1993 - "Delayed clearance of hepatitis B e antigen occurred more frequently in nonresponders who had elevated pretreatment serum transaminase levels. " 12/01/1993 - "Twenty-eight (28%) nonresponders had sustained clearance of hepatitis B e antigen during follow-up. " Order ALL the reference details at left...
2.	Lamivudine (3TC)FDA Link 08/01/2000 - "BACKGROUND/AIMS: Lamivudine is highly effective in suppressing hepatitis B viral replication and hepatic necroinflammatory activity. " 03/01/2009 - "RESULTS: Hepatitis B was treated successfully with lamivudine. " 03/01/2009 - "CONCLUSION: The obtained results suggest significant efficacy of lamivudine in patients with subacute hepatitis B. " 11/01/2004 - "It is also effective against lamivudine-resistant strains of hepatitis B mutations. " 07/01/2000 - "Clinical data show that lamivudine is an effective treatment for patients with pre-core mutant hepatitis B. " Order ALL the reference details at left...
3.	Hepatitis B e AntigensIBA 11/01/2009 - "This study shows that mean hepatic stiffness by elastography is significantly lower in patients with inactive hepatitis B compared to those with HBeAg-negative disease. " 12/01/1991 - "Other studies demonstrated that the mutant forms were observed with increasing frequency during the successful conversion from HBeAg positivity to anti-hepatitis B e antibody (anti-HBe) positivity. " 11/01/2009 - "An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers." 09/01/2009 - "Gender, nation, family history of hepatitis B and HBeAg were not associated with YMDD mutation (P more than 0.05), while the mutation rate was associated with the disease course and severity of disease. " 04/01/2009 - "Viral replication, however, can be restored to WT levels, if these polymerase mutations occur together with precore or basic core promoter substitutions as found in HBeAg-negative hepatitis B. " Order ALL the reference details at left...
4.	Hepatitis B Surface Antigens (HBsAg)IBA 01/01/2003 - "-B(Eng) had excellent protective efficacy against HBsAg carriage in healthy infants and children, and in neonates born to hepatitis B carrier mothers (protective efficacy of 95-99%). " 08/01/1994 - "The results show that long-term protection against HBsAg carriage of hepatitis B vaccination is very high and that a booster dose at school age does not significantly increase this protection." 12/01/1975 - "Future investigations should include methods to study: [a] the mechanisms of nonpercutaneous spread of hepatitis B virus, [b] the role of the individual with persisting HBSAg in the dissemination of hepatitis B virus, [c] the efficacy of hepatitis B immune globulin in high-risk areas, and [d] the effectiveness of various chemical and physical procedures in use for inactivation of hepatitis B virus using animal model systems." 12/01/1998 - "There was no significant difference in the donors' hepatitis B surface antibody titer before BMT for patients with or without serologic clearance of hepatitis B surface antigen (2255.2+/-4244.0 vs. 854.2+/-2306.7 mIU/mL; P=not significant). " 08/01/1990 - "High-anti-pre-S level in fulminant hepatitis B patients was assumed to be implicated in the fast clearance of HBsAg from circulation." Order ALL the reference details at left...
5.	DNA (Deoxyribonucleic Acid)IBA 01/27/2001 - "It is rapidly effective against virus replication since, after a one-month treatment, hepatitis B DNA levels are negative in most of the treated patients. " 08/01/2006 - "This first evaluation showed that DNA chip technology can provide important information in relation to the clinical management of chronic hepatitis B." 05/01/2009 - "Antiviral therapy against hepatitis B is effective in causing prolonged lowering of serum levels of hepatitis B virus DNA. " 12/01/2006 - "In conclusion, the quantitation of total and ccc HBV DNA in PBMCs is potentially useful as a non-invasive marker, and may help to increase our knowledge of the natural history of hepatitis B." 06/01/2005 - "CONCLUSIONS: These three sensitive assays, performed with the same DNA extraction, give clinicians useful information for the management of chronic hepatitis B and for timing treatment." Order ALL the reference details at left...
6.	hepatitis B hyperimmune globulinIBA 11/01/2000 - "Long-term immunoprophylaxis with hepatitis B immune globulin (HBIG) dramatically improved post-OLT survival, but recurrent HBV still occurred in up to 36% of the recipients. " 04/01/1982 - "Hepatitis B immune globulin (HBIG) is specific and effective for hepatitis B, but its value is offset by its high cost. " 08/01/2001 - "Long-term IV HBIG is effective in preventing recurrent hepatitis B. " 04/01/1993 - "For hepatitis B, we still believe the efficacy of HBIg, and in which patients with hepatitis B HBIg should be used, remains to be defined. " 04/01/1986 - "Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. " Order ALL the reference details at left...
7.	Immunoglobulins (Immunoglobulin)IBA 01/01/1982 - "Hepatitis B immunoglobulin is more effective than immune serum globulin. " 11/01/2009 - "Hepatitis B immunoglobulin and antiviral therapy was only partially effective in preventing HBV reinfection in patients with HCC recurrence." 01/01/2000 - "The hospital-wide hepatitis B immunisation programme helped to raise the immune status of the staff so as to reduce the costly prophylactic usage of hepatitis B immunoglobulin." 06/09/1989 - "Immunization with a recombinant vaccine without concomitant administration of hepatitis B immunoglobulin, therefore, considerably decreased the incidence of the carrier state." 02/01/1988 - "Prevention of horizontal transmission of hepatitis B: efficacy of hepatitis B immunoglobulin and vaccine in an institution for the handicapped." Order ALL the reference details at left...
8.	InterferonsIBA 01/01/2000 - "Hepatitis B immune globulin and interferon have been found to be effective in varying degrees. " 01/01/1990 - "Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study." 07/01/2009 - "Comments on the EASL practice guidelines for the management of chronic hepatitis B: controversies in interferon-based therapy." 02/01/1997 - "Preliminary data suggest that interferons may have a role in the management of chronic hepatitis B and C." 07/01/1995 - "Enumerates factors influencing the efficacy of interferon therapy and the outcome of viral hepatitis B." Order ALL the reference details at left...
9.	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 10/21/1976 - "They may be important determinants in assessing infectivity of chronic carriers of HBs Ag and in evaluating efficacy of hepatitis B immune globulin and hepatitis B vaccines." 01/01/1993 - "The hepatitis B vaccine, which was introduced to use in Thailand in 1985, seems to be effective in reducing the prevalence of hepatitis B carriers year after year. " 01/01/1985 - "Follow-up studies have demonstrated the effect of this prevention, and the newly developed hepatitis B vaccine has further improved the possibilities for effective prophylaxis against occupational hepatitis B. " 08/01/1998 - "Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B." 04/06/2001 - "Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan." Order ALL the reference details at left...
10.	Interferon-alpha (Interferon Alfa)FDA Link 06/01/1991 - "Incidence of hepatitis B viraemia, detected using the polymerase chain reaction, after successful therapy of hepatitis B virus carriers with interferon-alpha." 12/01/2002 - "Interferon alfa (IFN-alpha) therapy remains a mainstay of treatment in active hepatitis B. " 01/01/1995 - "CONCLUSIONS--Treatment with alpha interferon at doses of 3 MU/m2 is effective in children with active hepatitis B. " 07/01/1996 - "Specific therapies such as interferon alfa are now approved for treatment of chronic viral hepatitis B and C, with improvement in liver tests in up to 50% of patients while on treatment. " 07/01/1997 - "The data of dynamic monitoring of the production of alpha-interferon helped develop a test for predicting threatened chronic degeneration of light forms of hepatitis B. " Order ALL the reference details at left...

Therapies and Procedures

1.	Liver Transplantation 02/01/2009 - "The outcome of liver transplantation for hepatitis B has markedly improved in the last two decades. " 02/15/2003 - "The results of liver transplantation in these patients have significantly improved to a level comparable to those of other recipients as a result of the rapid evolution in the strategies of prevention and treatment of recurrent hepatitis B over the past decade. " 09/01/2002 - "BACKGROUND: Survival rates of hepatitis B patients after liver transplantation improved significantly by introduction of passive immunoprophylaxis. " 01/01/2003 - "This study was designed to analyse the influence of alloreactivity and immunosuppression, on the efficacy of adoptive immune transfer to hepatitis B by liver transplantation. " 09/27/2005 - "This modern antiviral managemant improved the outcome of hepatitis B patients after liver transplantation. " Order ALL the reference details at left...
2.	Transplants (Transplant) 10/01/2003 - "BACKGROUND: The aim of this study was to determine the role of hepatitis B virus (HBV) vaccination as defined by the seroconversion to hepatitis B surface antibody (anti-HBs) positivity in peripheral blood stem cell transplants. " 02/01/2001 - "The purpose of this study was to provide a prospective evaluation of the immunogenicity of the recombinant vaccine (RV) against Hepatitis B in pediatric patients with liver transplants (TxH) who for different reasons did not receive a pretransplantation vaccine. " 12/01/1995 - "Intensive study of transplant patients with hepatitis B has led to a new understanding of the immunobiology of hepatitis B virus." 09/01/2009 - "In conclusion, we found similar waitlist and post-transplant outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. " 09/01/2009 - "Data on post-transplant outcomes of African Americans and waitlist outcomes of Asian Americans and African Americans with hepatitis B are scant. " Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 12/01/2004 - "The combined therapy for chronic viral hepatitis B administered to liver transplant recipients at our centre showed very good outcomes. " 06/01/2006 - "Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation." 08/01/1992 - "Protection against hepatitis B was observed in 73.3% of the children evaluated prior to transplantation. " 08/01/1986 - "Protection against hepatitis B after marrow transplantation." 03/01/2000 - "Studies have recently questioned the significance of an isolated hepatitis B core antibody test in evaluating the suitability of solid organs for transplantation. " Order ALL the reference details at left...
4.	Renal Dialysis (Hemodialysis) 01/01/2007 - "Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients." 11/01/2009 - "In patients on hemodialysis with a history of failure to respond to hepatitis B vaccination, intradermal revaccination is more effective than repeat intramuscular vaccination. " 12/01/1998 - "The results show that intradermal hepatitis B vaccination response with a higher vaccination dose than previously used in hemodialysis patients is superior to conventional intramuscular and subcutaneous vaccination and is also well tolerated. " 08/01/2006 - "The aim of the present study was to compare the efficacy of intradermal hepatitis B vaccination with intramuscular vaccination in hemodialysis patients. " 08/01/2006 - "Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients." Order ALL the reference details at left...
5.	Drug Therapy (Chemotherapy) 07/01/2006 - "MATERIALS AND METHODS: Two hundred and thirty-three patients with unresectable HCC (mainly hepatitis B-associated) who were recruited into two separate randomized phase III clinical studies, based on palliative chemotherapy and palliative hormonal therapy, respectively, gave consent and received pretreatment QoL assessment. " 10/01/2009 - "Monitoring drug therapy for hepatitis B--a global challenge?" 11/01/2008 - "Reactivation of viral hepatitis B is a well-known complication in patients receiving chemotherapy or immunosuppressive therapy; its incidence reaches 50%. " 07/01/2008 - "METHODS: Bibliographic searches were carried out in the databases PubMed and EMBASE, using the search word <<hepatitis B>>, limited by <<drug therapy>> plus <<clinical trial>>, <<meta-analysis>> or <<guidelines>>, within the period 1991-2007. " 06/01/2008 - "Hepatitis B reactivation after chemotherapy: two decades of clinical research." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Hepatitis B

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 656 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>